Thomas S. Haas, D.O., FCAP, an anatomic and clinical pathologist at Mercy Hospital and Trauma Center in Janesville, WI, is a co-author of five recently published research papers. Two were published in the journal Applied Immunohistochemistry and Molecular Morphology of the Society for Applied Immunohistochemistry: “A New Rabbit Monoclonal E-Cadherin Antibody [EP700Y] Shows Higher Sensitivity Than Mouse Monoclonal E-Cadherin [HECD-1] Antibody in Breast Ductal Carcinomas and Does Not Stain Breast Lobular Carcinomas,” September 2014; and “Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma,” which was published online in January 2015 ahead of print due to the importance of the subject matter. In addition, the Archives of Pathology and Laboratory Medicine of the College of American Pathologists published three research papers that Haas co-authored: “A Newly Developed Uroplakin II Antibody with Increased Sensitivity in Urothelial Carcinoma of the Bladder,” July 2014; “An Immunohistochemical Analysis of a Newly Developed Mouse Monoclonal p40 (BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate, and Head and Neck Cancers,” October 2014; and “Principles of Analytic Validation of Immunohistochemical Assays,” November 2014. Due to his research and a number of other lecture/teaching activities, Haas was invited to participate in the College of American Pathologists panel that was assembled to hammer out the “Principles of Analytic Validation of Immunohistochemical Assays,” which is considered a recommendation “white paper” on this topic.
